Black Hawk Acquisition Corp

This unsecured credit facility supplies liquidity to fund potential trust extensions or operational runway without amending the statutory redemption deadline or encumbering public shareholder assets. The explicit trust account waiver shields investor proceeds from creditor claims if the SPAC dissolves, preserving redemption values intact. The $1.00 per share conversion mechanic caps sponsor dilution upside at deal close and activates automatic registration rights consistent with the March 20, 2024 registration agreement, clarifying post-transaction share class liquidity. No changes to the acquisition target, valuation parameters, or management roster are reported.

This filing is critical because it reveals that Black Hawk breached its governing documents by failing to make required extension payments within the cure period, and the Board chose not to liquidate. This creates legal exposure and could affect the validity of the business combination. The Nasdaq MVLS deficiency threatens continued listing. The $1.00 per share conversion price on sponsor notes (vs. ~$11.92 trust per share) will cause massive dilution to public shareholders. The PPM Investment condition ($10M) remains unmet and may be waived, potentially leading to delisting. These factors directly impact redemption decisions and the post-combination company's viability.

Trust per share is now $11.60, up from $11.22 at year-end, creating a small spread for remaining public holders. The sponsor and Vesicor are funding extensions via convertible notes and direct advances, but the SPAC still has a working capital deficit and a going concern warning. The Nasdaq deficiency adds a delisting risk if the merger is not completed or compliance regained before Sept 28, 2026. Vesicor's pre-money valuation is $70M, existing shareholders roll 100% equity, and Vesicor is funding half the extension payments and certain merger costs. The deal is now in Amendment No. 3 S-4 stage.

For an announced SPAC, missing a periodic filing deadline triggers exchange listing compliance reviews that can suspend trading, freeze shareholder redemption windows, or initiate delisting procedures before a merger vote or cash distribution occurs. The registrant attributed the delay to 'a delay experienced by the Registrant in completing its financial statement,' an accounting bottleneck that typically cascades into postponed auditor comfort letters, delayed trust reconciliations, and slower proxy finalization, thereby compressing the viable timeline for a business combination closing.

For investors monitoring SPAC execution mechanics, this filing introduces listing compliance risk without modifying the approved redemption timeline, trust distribution mechanics, extension schedule, or merger target trajectory. The filing explicitly notes that failure to meet the $50,000,000 benchmark by the September 28, 2026 deadline will trigger a written delisting notification. While the company outlines potential remediation routes—an appeal to a Nasdaq Listing Qualifications Panel or a request to transfer to the Nasdaq Capital Market—it attributes no guarantee to either outcome, stating there is 'no assurance' success. This listing vulnerability could compress secondary market liquidity and influence shareholder sentiment ahead of any combination vote, though the registrant confirmed no alterations to sponsor conduct, deal progress, or trust account terms.

Changes in target-company executive leadership directly influence de-risking timelines prior to SPAC shareholder redemption decisions. Appointing an external biotech veteran signals a strategic pivot to accelerate clinical milestones, specifically the cited 2027 IND submission target. The notably modest $48,000 starting salary, explicitly conditional upon securing $5 million in equity, highlights immediate liquidity requirements that likely necessitate a PIPE financing round or post-merger capital raise, introducing potential dilution risks for redemption-track investors before proxy deadlines arrive. Additionally, the granular severance and restrictive covenants clarify the post-combination governance framework and management incentive alignment, providing transparency on how operational control will shift following the transaction.

Investors must track the reduced trust balance and per-share value for future redemptions, the extended deadline to December 2026, the sponsor's commitment to fund monthly extension payments (some paid late), and the pending deal with Vesicor. The trust per-share value of $11.22 is above the IPO price but may change with further redemptions or interest. The material weakness and going-concern note signal execution risk.

The late extension payments and the Board's failure to liquidate create material legal risk—a court could conclude the SPAC should have liquidated, potentially invalidating the business combination or exposing directors to claims. The new convertible notes at $1.00/share conversion price will massively dilute public shareholders if converted (up to 1,000,000 shares). The PPM Investment condition is critical because if waived, Nasdaq listing standards for shareholders' equity may not be met, risking delisting. The sliding-scale founder share transfer changes post-closing ownership. The high redemption rate (69%) reduces trust cash and increases reliance on the uncertain PPM. Investors need to assess these risks before the shareholder vote.

For SPACs, delayed 10-K submissions directly compress the timeline to satisfy merger closing conditions, typically require audited financials, and can trigger automatic liquidation or mandatory extension votes if the corporate charter ties the deSPAC window to fiscal-year reporting deadlines. The postponement raises sponsor conduct and execution risk: Mr.

As structured by the sponsor and issuer, this financing architecture prevents trust account erosion during the announced deal’s execution phase, thereby preserving public shareholder redemption liquidity. The explicit carve-out for 'extension purposes' indicates tactical runway supplementation to support the timeline for the previously announced business combination without triggering early termination or margin calls. At maximum drawdown and full conversion, the instrument introduces a defined dilution vector of up to 300,000 shares, subject to standard registration protocols that do not impede post-merger trading. According to the filing signatures, Chief Executive Officer Kent Louis Kaufman authenticated the 8-K disclosure and COO Jonathan Ginsberg executed the Note. The document contains no forward-looking projections, customer acknowledgments, revenue commitments, market size estimates, technology roadmaps, commercial partnership validations, litigation exposures, or executive departures; it exclusively governs sponsor lending covenants and corporate finance contingencies.

The loss of a target company’s CFO mid-combination signals operational transition risk that may influence deal execution timelines and shareholder approval dynamics. Vesicor explicitly states that it believes Mr. Creem’s background, including more than 35 years in senior healthcare executive roles and prior tenure as CFO of ApolloMed, makes him well qualified to serve. Vesicor also asserts that it believes Mr. Field’s background, encompassing over 30 years in media and investments alongside founding Interscope Communications in 1982 and Radar Pictures in 2001, makes him well qualified for the board seat. The filing confirms neither appointee holds a family relationship with the SPAC’s directors or executives, has material interests under Regulation S-K Item 404(a), and was selected pursuant to separate arrangements. Because the new CFO operates without a signed employment contract, investors tracking post-merger integration readiness and management retention covenants should monitor for subsequent filings that may address deferred compensation, voting thresholds, or timeline amendments. The absence of mechanical updates leaves the existing redemption calendar and trust structure unaffected, but the personnel shift warrants close tracking for potential impacts on due diligence completion and SPAC sponsor alignment.

The filing is critical for investors tracking the deal's financing status and the potential for significant dilution. The closing is contingent on Vesicor procuring a $10 million PPM Investment, but no commitments have been received, and both Vesicor and Black Hawk may waive this condition. If waived, the combined company may not meet Nasdaq's $5 million shareholders' equity requirement and could be delisted. Additionally, the sponsor's $700,000 in convertible notes can be converted into 700,000 shares at a $1.00 per share conversion price, creating notable dilution for public shareholders. The filing also confirms Sponsor and Vesicor have each funded $750,000 in extension payments, and outlines the potential transfer of up to 865,000 Founder Shares to Vesicor shareholders based on a sliding scale.

This filing contains critical mechanics for redemption calendar, trust value, and deal completion. Only ~$2.6M in non-trust cash existed as of Aug. 31, 2025 ($15k cash, working capital deficit of ~$902k). The massive July 2025 redemptions (69.2% of shares) left only $22.7M in trust. The combination of $700k in sponsor notes convertible at $1.00/share (a ~90% discount to the $10.97 trust value per share) creates severe potential dilution: up to 700,000 shares could be issued to the sponsor at well below trust value. The deal is at risk of failure to meet Nasdaq listing standards if the $10M PPM Investment is not completed; the document explicitly warns that waiver of the PPM condition would cause the combined company to not satisfy the $5M shareholders' equity requirement, risking delisting to the OTC market. The $70M valuation is based on equity value / redemption price, so the higher the redemptions, the fewer shares Vesicor holders get relative to the fixed $70M numerator, altering ownership splits significantly. The filing is also material for its extensive disclosure of Sponsor conflicts: founder shares acquired for $25k now worth ~$9.4M at $10.97 trust value; extension payments represent capital at risk that incentivizes closing any deal.

This administrative toll halts the statutory clock for S-4 effectiveness, thereby deferring any downstream shareholder meeting, proxy solicitation, or redemption deadline contingent on an active registration statement. The filing introduces no new valuation metrics, cash extension provisions, or revised deal structures. Because the registrant relies on the standard Rule 473 waiver rather than amending specific term sheets or shareholder approval thresholds, existing sponsor commitments and the target transaction’s status remain unaltered.

This filing is the primary disclosure document for the de-SPAC vote. The material risk is the PPM condition: the target itself is uncertain it will close the $10M PIPE. If the condition is waived and shares are delisted, public shareholders may face an over-the-counter market and a potential near-total loss of liquidity. The near-70% redemption rate and the sponsor's ability to convert notes at a 90% discount ($1 vs $10 IPO) are significant sponsor conduct signals. The target is at the preclinical stage and its key technology claims are based on unverified case studies from Japan that Vesicor explicitly states cannot be relied upon.

This filing is material because it provides the first detailed financial update since the announcement of the definitive business combination with Vesicor, a biotech company developing p53-based cancer therapeutics. The trust account per-share value has dropped from $10.41 to $10.97 (adjusted for redemptions), but the trust has been cut by two-thirds. The extension terms ($150,000/month) and sponsor convertible notes reveal the company's reliance on sponsor support to survive. The going concern disclosure and working capital deficit indicate significant risk. The filing also discloses the death of a board member, which may affect governance. All these factors directly impact redemption deadlines, trust value, and deal completion probability.

While the notification carries no direct weight on deal valuation or shareholder payout formulas, it signals an accounting or audit preparation bottleneck at the sponsor level that investors in a PIPE-adjacent or arbitrage position typically price into liquidity spreads. Under Rule 12b-25, the company must file on or before the fifth calendar day following the original due date; missing that window invites exchange listing deficiency notices, which historically constrain secondary trading volume and can complicate final shareholder vote timing relative to hard redemption deadlines.

Public shareholders now face a revised liquidation horizon of October 22, 2025, which dictates the final window to exercise redemption rights before a potential dissolution vote. The $150,000 deposit directly increases the aggregate trust balance held for public holders, though per-share trust math is not restated. The exhibit discloses no updates on target pipeline negotiations, operational metrics, technology roadmap, partnerships, or litigation, and carries no written communications or soliciting material flags. Chief Executive Officer Kent Louis Kaufman signed the report on behalf of the registrant.

The disclosure materially alters redemption timing and post-deal survival odds: the explicit waiver pathway for the $10,000,000 PPM investment creates direct Nasdaq delisting exposure if trust proceeds are exhausted, while the strict two-business-day certificate delivery deadline removes the traditional SPAC 'option window' for retail exit.

The filing mechanically pushes the SPAC redemption and merger deadline forward by exactly one calendar month to September 22, 2025, financed through a discrete $150,000 contribution. Beyond confirming the extension trigger and trustee funding event, the document contains no disclosures regarding a target entity, proposed transaction size, pipeline progression, customer contracts, operational metrics, technology, strategic partnerships, litigation, or executive transitions outside the routine signature block.

Because the text operates solely as a routine compliance authorization listing executive titles and corporate office addresses in Tokyo and New York, it yields no substantive data on target revenue streams, customer concentrations, addressable markets, strategic initiatives, technology development, partnership structures, active litigation, or senior leadership movements beyond the named signatories. The filing represents standard administrative housekeeping for beneficial ownership reporting under Section 13(d) and Section 13(g) of the Exchange Act and carries no direct bearing on shareholder liquidity mechanics, deal financing conditions, or sponsor accountability metrics. false, 0.95

The extension materially resets the redemption window and trust timeline. Public shareholders retain their cash-out rights through August 22 2025, delaying any mandatory trust distribution or liquidation event. The $150,000 deposit signals active sponsor funding of monthly extensions, which typically comes from related parties or insiders and is credited to preserve per-share trust balances for redeeming holders. Chief Executive Officer Kent Louis Kaufman executed the report on August 7, 2025. Aside from the extension mechanics, the filing restates standard corporate identifiers: the company is incorporated in the Cayman Islands, operates from Suite 166 at 4125 Blackhawk Plaza Circle in Danville, California, retains an Emerging Growth Company election without opting out of extended transition periods, and lists Units (BKHAU), Ordinary Shares (BKHA), and Rights (BKHAR) on The Nasdaq Stock Market LLC under SIC 2836. No target identification, revenue metrics, strategic partnerships, litigation, or personnel changes are reported in this submission.

The submission confirms that a corporate insurer has registered a passive equity position in Black Hawk Acquisition Corp., but the provided text contains zero claims regarding customers, revenue, market size, strategy, technology, partnerships, litigation, or personnel. All observations regarding the absence of financial metrics, deal timeline updates, and mechanical indicators are attributed directly to the limited scope of the submitted filing excerpt, which discloses no numerical figures whatsoever.

Per the proxy statement, the extended deadline and funded extension payments align sponsor economic survival with deal completion while isolating liquidity execution risk on Vesicor to independently raise $10,000,000.00 concurrently with closing. The agreement structures founder share transfers from the Sponsor to Vesicor stockholders on a sliding scale tied to unmet capital thresholds, directly linking insider wealth preservation to PIPE success.

What changed: Quarterly report on Form 10-Q for Black Hawk Acquisition Corp (BKHA), a SPAC that has announced a merger with Vesicor Therapeutics. The filing is the regular quarterly report for the period ended May 31, 2026. Key developments: (1) The merger with Vesicor (pre-money $70 million) remains pending; Amendment No. 3 to the S-4 was filed on March 4, 2026. (2) On March 31, 2026, Nasdaq notified the Company that its MVLS had fallen below $50 million for 30 consecutive business days; the Company has 180 days (to Sept 28, 2026) to regain compliance. (3) As of May 31, 2026, the trust holds $25,313,116 (at $11.92/share for 2,124,077 redeemable shares), up from $23,827,149 at Nov 30, 2025. (4) Vesicor forgave $1,015,988 of its advances (June 30, 2026), which will reduce the 'Due to target company' liability. (5) Working capital deficit was $2,688,676 and cash was $11,583; the Company reasserts a going concern doubt. (6) The convertible notes from the Sponsor ($1,232,366 outstanding) were modified to a fixed $1.00/share conversion price, qualifying for equity scope exception. (7) The Company is current on its $150,000/month extension payments through Dec 22, 2026. (8) Net income for the six months was $228,734 vs $1,178,921 in the prior-year period. Why it matters: The trust value is $11.92 per share, well above typical trust levels. The Company has cash liquidity concerns (only $11,583 outside trust) and faces a Nasdaq delisting notice. Vesicor's forgiveness of $1,015,988 will improve the balance sheet. The merger is still pending with no hard closing date.

What changed: Amendment No. 6 to Registration Statement on Form S-4 (proxy statement/prospectus) for the business combination between Black Hawk Acquisition Corp (SPAC) and Vesicor Therapeutics, Inc., including proposals for domestication, merger, organizational documents, director election, Nasdaq issuance, incentive plan, NTA amendment, and adjournment. Updated disclosures include: (1) detailed description of late November and December 2025 extension payments, cure period expiration, and risk that a court could determine liquidation should have been initiated; (2) revised risk factors regarding potential delisting if PPM Investment ($10M) not obtained; (3) disclosure of Debt Forgiveness Agreement where Vesicor forgave $1,015,987.50 in advances; (4) updated pro forma financial statements under no, 50%, and maximum redemption scenarios; (5) updated share ownership tables with sliding scale Founder Share transfer mechanism (up to 865,000 shares); (6) inclusion of fairness opinion from EntrepreneurShares LLC; (7) trust balance of approximately $22.7 million after 69.2% public share redemption. Why it matters: This filing provides the definitive proxy statement for shareholder vote on the de-SPAC transaction. It reveals that the SPAC may have been required to liquidate due to late extension payments, creating legal uncertainty. The PPM Investment condition could be waived, risking Nasdaq listing. Sponsor convertible notes at $1.00/share will cause significant dilution. The Founder Share sliding scale mechanism could transfer up to 865,000 shares to target. Shareholders must consider these risks before voting.

What changed: Amendment No. 5 to Registration Statement on Form S-4 (S-4/A) — a proxy statement/prospectus filed by Black Hawk Acquisition Corp (BKHA) in connection with its proposed business combination with Vesicor Therapeutics, Inc. It is both a solicitation of proxies for an extraordinary general meeting and a prospectus for the securities to be issued by the post-combination company. This Amendment No. 5 updates the registration statement to include: (1) disclosure of late monthly extension payments (Nov 2025, Dec 2025) that were deposited after their respective cure periods expired, and the SPAC's decision not to liquidate despite acknowledging a breach of its governing documents; (2) a new May 2026 Convertible Note to the Sponsor for $300,000; (3) updated financial statements (Black Hawk unaudited for three months ended Feb 28, 2026; Vesicor unaudited for three months ended Mar 31, 2026); (4) updated pro forma financial information assuming multiple redemption scenarios; and (5) a sliding-scale mechanism for up to 865,000 Founder Shares that may be transferred to Vesicor shareholders post-closing depending on capital raised and post-de-SPAC stock price. Why it matters: The filing is highly material. It contains the first explicit disclosure that BKHA breached its charter and trust agreement by failing to make two monthly extension payments within the applicable cure periods and did not initiate liquidation as required. The SPAC acknowledges a court could conclude liquidation should have occurred, and that the SPAC and its directors could be subject to claims. This creates significant legal risk and uncertainty for the business combination. The filing also confirms the trust holds approximately $24.6M after the July 2025 redemptions of 69.2% of public shares. The SPAC must close a deal by Dec 22, 2026, per the extension plan, but its own past non-compliance undermines the structural integrity of that timeline. The sponsor's $1.3M in convertible notes at $1.00/share also create a massive dilutive incentive favoring closure over liquidation. The target, Vesicor, is a pre-revenue, pre-clinical biotech with no patents and a sole product candidate yet to commence IND-enabling studies, introducing high execution risk.

What changed: A Form 8-K current report announcing the execution of a convertible promissory note. Per Exhibit 10.1 attached to the filing, Black Hawk Acquisition Corp. entered into a financing arrangement with its sponsor, Black Hawk Management LLC, authorizing drawdowns of up to $300,000 for working capital and extension purposes. The note accrues interest at 10% per annum, commencing April 20, 2026, for a period of one year. Sponsor may request funds with issuance occurring within five business days. Upon completion of an initial business combination, the Sponsor holds the unilateral election to receive cash repayment or convert the outstanding principal into post-transaction ordinary shares at a fixed conversion price of $1.00 per share. In the event of liquidation, the note matures for cash payment, but the Sponsor expressly waived all claims and recourse against the company’s trust account. Why it matters: This unsecured credit facility supplies liquidity to fund potential trust extensions or operational runway without amending the statutory redemption deadline or encumbering public shareholder assets. The explicit trust account waiver shields investor proceeds from creditor claims if the SPAC dissolves, preserving redemption values intact. The $1.00 per share conversion mechanic caps sponsor dilution upside at deal close and activates automatic registration rights consistent with the March 20, 2024 registration agreement, clarifying post-transaction share class liquidity. No changes to the acquisition target, valuation parameters, or management roster are reported.

What changed: S-4/A (Amendment No. 4) — Preliminary proxy statement/prospectus for the extraordinary general meeting of Black Hawk Acquisition Corporation to approve the business combination with Vesicor Therapeutics, Inc., including the domestication from Cayman Islands to Delaware, merger, and related proposals. Amendment No. 4 updates the S-4 with: (1) disclosure that Black Hawk failed to timely deposit extension payments for November 2025 and December 2025, with the November payment made after the 45-day cure period expired, constituting a breach of the Current Charter and Trust Agreement; (2) the Board decided not to initiate liquidation despite the breach, creating potential litigation risk; (3) disclosure of a February 12, 2026 convertible note to the Sponsor for $300,000 at 10% interest, convertible at $1.00 per share; (4) receipt of Nasdaq MVLS deficiency notice on March 31, 2026, with a compliance period through September 28, 2026; (5) updated financial statements and pro forma information; (6) addition of employment agreements for PubCo executives; (7) revised risk factors including risks related to the extension payment breach and potential delisting. Why it matters: This filing is critical because it reveals that Black Hawk breached its governing documents by failing to make required extension payments within the cure period, and the Board chose not to liquidate. This creates legal exposure and could affect the validity of the business combination. The Nasdaq MVLS deficiency threatens continued listing. The $1.00 per share conversion price on sponsor notes (vs. ~$11.92 trust per share) will cause massive dilution to public shareholders. The PPM Investment condition ($10M) remains unmet and may be waived, potentially leading to delisting. These factors directly impact redemption decisions and the post-combination company's viability.

What changed: Amendment No. 1 to Black Hawk Acquisition Corporation's Form 10-K for the fiscal year ended November 30, 2025, originally filed March 6, 2026. It is filed solely to add the board-adopted Compensation Recovery (Clawback) Policy as Exhibit 97.1, which was inadvertently omitted; no other change is made and it does not update disclosure for later events. The cover page repeats that non-affiliate market value was approximately $73.9 million at May 31, 2025 and that 4,153,577 ordinary shares were outstanding at March 6, 2026. Why it matters: This is an exhibit-only correction with no economic content: no financial statement, trust figure, deadline or transaction disclosure changes, and the amendment expressly does not reflect events after the original March 6, 2026 filing. It matters only in the narrow sense that a missing clawback policy exhibit is a listing-rule compliance item that exchanges expect annual reports to carry, and the company has now cured it. Nothing here should change a view on Black Hawk's trust value or timeline.

What changed: Quarterly report (Form 10-Q) for Black Hawk Acquisition Corp (BKHA), a blank-check SPAC that has announced a merger with Vesicor Therapeutics. Trust value rose to $24.6M from $23.8M as of Nov 30, 2025. Extension deposits continued; convertible note balance increased to $997k from $595k. New $7k due to related party. Vesicor advanced $441k to the SPAC during the quarter. The Company deposited $600k into the Trust during the quarter. A Nasdaq deficiency notice was received on March 31, 2026 for MVLS falling below $50M. Why it matters: Trust per share is now $11.60, up from $11.22 at year-end, creating a small spread for remaining public holders. The sponsor and Vesicor are funding extensions via convertible notes and direct advances, but the SPAC still has a working capital deficit and a going concern warning. The Nasdaq deficiency adds a delisting risk if the merger is not completed or compliance regained before Sept 28, 2026. Vesicor's pre-money valuation is $70M, existing shareholders roll 100% equity, and Vesicor is funding half the extension payments and certain merger costs. The deal is now in Amendment No. 3 S-4 stage.

What changed: A Form 12b-25 Notification of Late Filing for a Quarterly Report on Form 10-Q. This notice documents that Black Hawk Acquisition Corporation missed the prescribed April 14, 2026 filing deadline for its quarterly report covering the period ended February 28, 2026. Regarding redemption deadlines, trust value mechanics, extension votes, deal progress, and sponsor conduct, the filing discloses no changes to any of these parameters. Why it matters: For an announced SPAC, missing a periodic filing deadline triggers exchange listing compliance reviews that can suspend trading, freeze shareholder redemption windows, or initiate delisting procedures before a merger vote or cash distribution occurs. The registrant attributed the delay to 'a delay experienced by the Registrant in completing its financial statement,' an accounting bottleneck that typically cascades into postponed auditor comfort letters, delayed trust reconciliations, and slower proxy finalization, thereby compressing the viable timeline for a business combination closing.

What changed: Form 8-K (Item 3.01) disclosing a Nasdaq Market Value of Listed Securities (MVLS) deficiency notice. The Nasdaq Listing Qualifications Department stated on March 31, 2026, that Black Hawk Acquisition Corporation’s MVLS fell below the $50,000,000 requirement for the trailing 30 consecutive business days. Acting through Chief Executive Officer Kent Louis Kaufman, the registrant reported it has a 180-calendar-day cure period ending September 28, 2026. To regain compliance, the company must maintain an MVLS of $50,000,000 or higher for a minimum of ten consecutive business days, though Nasdaq may exercise discretion to require up to twenty consecutive business days. Trading of units (BKHAU), rights (BKHAR), and class A ordinary shares (BKHA) will remain uninterrupted on the Nasdaq Global Market during the cure window. Why it matters: For investors monitoring SPAC execution mechanics, this filing introduces listing compliance risk without modifying the approved redemption timeline, trust distribution mechanics, extension schedule, or merger target trajectory. The filing explicitly notes that failure to meet the $50,000,000 benchmark by the September 28, 2026 deadline will trigger a written delisting notification. While the company outlines potential remediation routes—an appeal to a Nasdaq Listing Qualifications Panel or a request to transfer to the Nasdaq Capital Market—it attributes no guarantee to either outcome, stating there is 'no assurance' success. This listing vulnerability could compress secondary market liquidity and influence shareholder sentiment ahead of any combination vote, though the registrant confirmed no alterations to sponsor conduct, deal progress, or trust account terms.

What changed: A Form 8-K current report accompanying an executive employment agreement (Exhibit 10.1) and a corporate press release (Exhibit 99.1), filed pursuant to Items 5.02 and 7.01. Black Hawk Acquisition Corp reported that its proposed business combination target, Vesicor Therapeutics, Inc., appointed Dr. Michael Tolentino as Chief Executive Officer effective March 17, 2026, replacing founding CEO Luo Feng, who transitioned to Chief Scientific Officer. The attached employment contract establishes a three-year initial term, a $48,000 base salary (subject to upward revision if Vesicor raises a minimum of $5 million in equity capital), an ad hoc annual bonus at the Board's discretion, and a severance package equating to two times base salary plus target bonus, alongside 24 months of health insurance premium reimbursements, triggered by termination without cause or for Good Reason. The agreement enforces a non-competition clause for the employment duration plus one year, a 12-month non-solicitation covenant, and comprehensive intellectual property assignment under Florida law. In the accompanying press release, Vesicor reiterated its development roadmap, targeting an FDA IND submission in 2027 for its p53-based cancer therapeutics delivered via precision-engineered microvesicles, while confirming ongoing efforts to finalize the de-SPAC merger with Black Hawk. Why it matters: Changes in target-company executive leadership directly influence de-risking timelines prior to SPAC shareholder redemption decisions. Appointing an external biotech veteran signals a strategic pivot to accelerate clinical milestones, specifically the cited 2027 IND submission target. The notably modest $48,000 starting salary, explicitly conditional upon securing $5 million in equity, highlights immediate liquidity requirements that likely necessitate a PIPE financing round or post-merger capital raise, introducing potential dilution risks for redemption-track investors before proxy deadlines arrive. Additionally, the granular severance and restrictive covenants clarify the post-combination governance framework and management incentive alignment, providing transparency on how operational control will shift following the transaction.